Questions
ghk cu post surgery: Frequently asked questions
Source-derived answers connected to this topic. Only stored records are displayed.
What If I'm Diabetic — Does GHK-Cu Still Work?
Yes, with caveats. The 2018 diabetic rat study showed GHK-Cu bypassed glucose-dependent fibroblast impairments, restoring closure rates to 89% of healthy controls. However, diabetic patients have delayed inflammatory resolution and higher infection risk. GHK-Cu addresses the fibroblast and remodeling deficits but doesn't fix underlying immune dysfunction. Use under physician supervision; standard diabetic wound care (glucose control, offloading, infection monitoring) remains essential.
What If the Wound Is Deep — Does Topical GHK-Cu Reach Subcutaneous Tissue?
Topical formulations penetrate 1–2mm into dermis but don't reach subcutaneous fat or fascia. For deep surgical wounds (>3mm depth), the peptide primarily benefits superficial epithelialization and dermal collagen remodeling. Deeper tissue healing relies on systemic delivery. Some research protocols use subcutaneous injection near the wound margin (0.5–1.0mg per injection site), but this isn't standard clinical practice. The strongest evidence supports topical use for surface-level healing; injectable protocols remain experimental.
What If My Incision Shows Signs of Infection While Using GHK-Cu?
Stop peptide application immediately and contact your surgical team. Infection requires antibiotic intervention. GHK-Cu has no antimicrobial activity and should not be applied to infected tissue. Signs include increasing redness beyond the immediate incision margin, purulent drainage, fever above 100.4°F, or worsening pain after initial post-op pain has begun subsiding. Once infection clears and your surgeon confirms the wound is clean, GHK-Cu can be resumed to support the healing process going forward.
What If I Miss Several Days of GHK-Cu Application During Recovery?
Resume twice-daily application as soon as you remember. The peptide remains effective throughout the entire proliferative and remodeling phases, which extend 6–12 weeks post-surgery. Missing 3–4 days doesn't negate prior benefit; cellular signaling effects are cumulative rather than dose-dependent in an all-or-nothing sense. Consistency matters most during weeks 2–6 when collagen deposition is most active, but even sporadic application delivers measurable benefit compared to no application.
What If I Start GHK-Cu Application Too Early After Surgery?
Wait until the incision has achieved primary closure. Typically 48–72 hours post-procedure depending on surgical type. Applying GHK-Cu during active hemostasis can theoretically interfere with platelet aggregation and clot stabilization, though no clinical reports document this occurring at standard topical concentrations. Your surgeon will confirm when the wound is closed and appropriate for topical treatment. Starting on day three rather than day one doesn't meaningfully reduce efficacy since the proliferative phase. Where GHK-Cu delivers maximum benefit. Peaks between days 4–14 post-surgery.
What If I Apply GHK-Cu Immediately After Surgery — Is That Too Early?
Apply after the hemostasis phase completes (typically 24–48 hours post-surgery when bleeding has fully stopped). Premature application during active clot formation can interfere with platelet aggregation. GHK-Cu's MMP-modulating effects may destabilize the provisional fibrin matrix before it's fully cross-linked. Wait until sutures are placed and initial clot stabilization occurs. Research protocols typically begin application 48 hours post-op, continuing through day 21 (the proliferative phase).